Skip to main content

Duke, LabCorp Form Personalized Medicine JV

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Duke University and Laboratory Corporation of America announced today that they have formed a joint venture focused on commercializing biomarkers for pharmacogenomic applications.

The joint venture will be known as The Biomarker Factory and combine Duke's efforts in biomarker discovery and validation with LabCorp's expertise in developing and marketing diagnostic and lab tools. The goal of the new JV is to "speed the translation of newly discovered biomarkers into widely available clinical tools that can measure individual therapeutic responses, predict disease progression, and evaluate any number of biologic or disease-causing processes," the partners said in a statement.

The Biomarker Factory will make use of Duke's collection of biological samples — numbering in the hundreds of thousands — and an infrastructure already in place in a large Duke-led epidemiology study called MURDOCK, which is in the process of recruiting 50,000 people into a registry. The JV also will utilize LabCorp's biorepository that is being developed to discover and validate biomarkers in human disease.

"The Biomarker Factory will position Duke and LabCorp on an end-to-end pathway from the research bench to the physician office," David King, chairman and CEO of LabCorp, said in a statement. "The Biomarker Factory will contribute greatly to the realization of the promise of individualized medicine and will assist physicians in understanding how to use newly developed biomarkers to improve patient outcomes and reduce healthcare costs."

Financial and further terms of the alliance were not disclosed.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.